Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C2 | P52895 | 3/20 | 0.50 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.50 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TPMT | P51580 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | MYC | P01106 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6632782 | 0.80 | CA12 (0.41) | CA1CA2ALDH1A1TP53HSD17B10 | |
| SCHEMBL6630470 | 0.80 | CA1 (0.45) | AKR1C2AKR1C1AKR1C4AKR1C3CA1 | |
| SCHEMBL27515038 | 0.77 | KEAP1 (0.42) | AKR1C2AKR1C1CA1CA2ALDH1A1 | |
| SCHEMBL6242319 | 0.72 | ALDH1A1 (0.51) | ALDH1A1HSD17B10HPGDCYP3A4TSHR | |
| SCHEMBL13537088 | 0.70 | AKR1C4 (0.56) | AKR1C2AKR1C1AKR1C4AKR1C3CA1 | |
| SCHEMBL1614777 | 0.69 | CYP3A4 (0.71) | AKR1C2AKR1C1AKR1C4AKR1C3CA1 | |
| SCHEMBL20397 | 0.69 | — | — | |
| SCHEMBL27670869 | 0.69 | — | — | |
| SCHEMBL15864848 | 0.68 | CA1 (0.53) | AKR1C2AKR1C1AKR1C4AKR1C3CA1 | |
| SCHEMBL27465063 | 0.68 | CA1 (0.42) | AKR1C2AKR1C1AKR1C4AKR1C3CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130078213-A1 | THROMBOPOIETIN MIMETICS | GLAXOSMITHKLINE LLC | 2013-03-28 | — | — | US | disclosed |
| CN-101343251-B | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP | 2011-11-09 | — | — | CN | disclosed |
| CN-101343250-B | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP | 2011-09-21 | — | — | CN | disclosed |
| EP-1889838-B1 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP (US) | 2009-10-14 | — | — | EP | disclosed |
| CN-101342169-A | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP (US) | 2009-01-14 | — | — | CN | disclosed |
| CN-101343251-A | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP (US) | 2009-01-14 | — | — | CN | disclosed |
| CN-101343250-A | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP (US) | 2009-01-14 | — | — | CN | disclosed |
| CN-100423721-C | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP (US) | 2008-10-08 | — | — | CN | disclosed |
| EP-1889838-A1 | Thrombopoietin mimetics | SmithKline Beecham Corporation (US) | 2008-02-20 | — | — | EP | disclosed |
| EP-1864981-A1 | Thrombopoietin mimetics | SmithKline Beecham Corporation (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20070129338-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION | 2007-06-07 | — | — | US | disclosed |
| US-20040019190-A1 | Thrombopoietin mimetics | NOVARTIS AG (CH) | 2004-01-29 | — | — | US | disclosed |
| EP-1294378-A4 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2004-01-28 | — | — | EP | disclosed |
| CN-1444477-A | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP (US) | 2003-09-24 | — | — | CN | disclosed |
| EP-1294378-A2 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001089457-A2 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129338-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | AKR1C2 3407/4885AKR1C1 2862/4885AKR1C4 3676/4885 |
| US-20130078213-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | AKR1C2 3407/4885AKR1C1 2862/4885AKR1C4 3676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.